Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer.
Our understanding of the tumor microenvironment continues to evolve and allows for the identification of biomarkers that should detect the presence of early stage malignancies. Recent advances in computational analysis and biomedical technologies have come together to elucidate signatures associated with cancer and that are capable of identifying unique tumor-specific proteins. Within the tumor microenvironment, we continue to characterize the proteophysiology of the different steps associated with tumor progression. The urgent need for biomarkers accurately detecting early-stage epithelial ovarian cancer has prompted us, and others, to engage in a search for specific peptide signatures that may discriminate transformed cells from those of the normal ovarian microenvironment. This endeavor also provides new insights into the biology of the disease, which may not only be applicable to detection but may also help to initiate new therapies and optimize patient care.
Lee
Catherine J
CJ
Department of Obstetrics and Gynecology, New York University School of Medicine, New York, New York 10016, USA.
Ariztia
Edgardo V
EV
Fishman
David A
DA
D014408:Biomarkers, Tumor; D002277:Carcinoma / Q000175:diagnosis*; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D040901:Proteomics
D014408:Biomarkers, Tumor